✦ LIBER ✦

Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials

✍ Scribed by Kohei Shitara, Junko Ikeda, Tomoya Yokota, Daisuke Takahari, Takashi Ura, Kei Muro, Keitaro Matsuo

Book ID: 113064501
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 288 KB
Volume: 30
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-011-9648-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tumor response and progression-free surv

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer : Findings on the basis of North Central Cancer Treatment Group trials

✍ Nathan R. Foster; Yingwei Qi; Qian Shi; James E. Krook; John W. Kugler; James R. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

CA125 level as a predictor of progressio

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

✍ Margrit M. Juretzka; Richard R. Barakat; Dennis S. Chi; Alexia Iasonos; Jakob Du 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Biomarker Profiles and Cytoplasmic Vacuo

Biomarker Profiles and Cytoplasmic Vacuolization as Predictors of Progression-Free Survival and Clinical Response to Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer

✍ A. Mahdavi; S. Chopra; M. Hunter; W. Brewster; I. Ramzy; K.S. Tewari 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Intermittent/alternated therapy with tam

Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863)

✍ L Beex; C Rose; H Mouridsen; J Jassem; M Nooy; J Estape; R Paridaens; M.J Piccar 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Estimating survival gain for economic ev

Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

✍ N. Neymark; I. Adriaenssen; T. Gorlia; S. Caleo; M. Bolla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

## Abstract The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival t

Is the progression free survival advanta

Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

✍ B. Smith; D. Cohn; A. Clements; B. Tierney; J. Straughn 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 105 KB